ORIGINAL ARTICLE
Lithium and suicide in mood disorders: Updated meta-review of the scientific literature
Katharine A Smith,
Andrea Cipriani,
Katharine A Smith
Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Search for more papers by this authorCorresponding Author
Andrea Cipriani
Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Correspondence
Andrea Cipriani, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
Email: [email protected]
Search for more papers by this authorKatharine A Smith,
Andrea Cipriani,
Katharine A Smith
Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Search for more papers by this authorCorresponding Author
Andrea Cipriani
Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
Correspondence
Andrea Cipriani, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
Email: [email protected]
Search for more papers by this authorAbstract
Objectives
Suicide and suicidal behaviour are increased in mood disorders, particularly bipolar disorders. Observational studies and small randomized controlled trials (RCTs) support the idea that taking lithium is associated with a reduction in these rates. This paper aims to review the best evidence for the effect of lithium on rates of suicide and self harm.
Methods
We searched PubMed, PsycINFO, and the Cochrane Library systematically for systematic reviews and meta-analyses of RCTs of lithium and suicide and self harm published between January 1980 and June 2017. In the case of multiple publications on the same topic, only the most recent or most comprehensive review was considered.
Results
A large number of reviews were identified, but only 16 publications were systematic reviews. Of these, three systematic reviews of lithium and suicide rates and one of lithium and self harm confined only to RCTs were identified. Despite some methodological concerns and heterogeneity in terms of participants, diagnoses, comparators, durations, and phase of illness, the evidence to date is overwhelmingly in favour of lithium as an antisuicidal agent, even balanced against any potential disadvantages of its use in regular clinical practice.
Conclusions
The anti-suicidal effects of lithium have been consistently reported over the past 40 years. The most robust evidence comes from RCTs, but these results are also discussed in the context of the difficulties in conducting high quality studies in this area, and the supporting evidence that observational and non-randomized studies can also provide. Given this evidence, however, the use of lithium is still underrepresented in clinical practice and should be incorporated more assertively into current guidelines.
REFERENCES
- 1Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015; 49: 1087-1206.
- 2Latalova K, Kamaradova D, Prasko J. Suicide in bipolar disorder: a review. Psychiatr Danub. 2014; 26.
- 3Tondo L, Lepri B, Baldessarini RJ. Suicidal risks among 2826 Sardinian major affective disorder patients. Acta Psychiatr Scand. 2007; 116: 419-428.
- 4Pompili M, Gonda X, Serafini G, et al. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord. 2013; 15: 457-490.
- 5Saunders KE, Hawton K. Clinical assessment and crisis intervention for the suicidal bipolar disorder patient. Bipolar Disord. 2013; 15: 575-583.
- 6Valtonen H, Suominen K, Partonen T, Ostamo A, Lönnqvist J. Time patterns of attempted suicide. J Affect Disord. 2006; 90: 201-207.
- 7Saunders KE, Hawton K. The role of psychopharmacology in suicide prevention. Epidemiol Psychiatr Sci. 2009; 18: 172-178.
- 8 World Health Organization. Preventing suicide: a global imperative. World Health Organization. 2014. http://www.who.int/mental_health/suicide-prevention/world_report_2014/en/. Accessed August 16, 2017.
- 9 Department of Health. Preventing Suicide in England: A Cross-Government Outcomes Strategy to Save Lives. London: Her Majesty's Government/Department of Health; 2012.
- 10 National Institute for Health and Clinical Excellence. Self-harm: Longer-term management. National Institute for Health and Clinical Excellence; 2011. (https://www.nice.org.uk/guidance/cg133)
- 11 Office of the Surgeon General (US, National Action Alliance for Suicide Prevention (US. 2012 National strategy for suicide prevention: goals and objectives for action: a report of the US Surgeon General and of the National Action Alliance for Suicide Prevention.
- 12Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016; 30: 495-553
- 13Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014; 1: 351-359.
- 14Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry. 2003; 64(Suppl5): 44-52.
- 15Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003; 290: 1467-1473.
- 16Collins JC, McFarland BH. Divalproex, lithium and suicide among medicaid patients with bipolar disorder. J Affect Disord. 2008; 107: 23-28.
- 17Søndergård L, Lopez AG, Andersen PK, Kessing LV. Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord. 2008; 10: 87-94.
- 18Isometsä E, Sund R, Pirkola S. Post-discharge suicides of inpatients with bipolar disorder in Finland. Bipolar Disord. 2014; 16: 867-874.
- 19Toffol E, Hätönen T, Tanskanen A, et al. Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: a nationwide registry-based prospective cohort study. J Affect Disord. 2015; 183: 159-165.
- 20Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000; 57: 481-489.
- 21Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003; 64: 1013-1024.
- 22Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003; 60: 392-400.
- 23 BALANCE investigators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010; 375: 385-395
- 24Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006; 8(5p2): 625-639
- 25Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry. 2005; 162: 1805-1819.
- 26Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013; 346: f3646.
- 27Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006; 163: 41-47.
- 28Egger M, Smith GD. Bias in location and selection of studies. Br Med J. 1998; 316: 61.
- 29Hayes JF, Pitman A, Marston L, et al. Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: a UK population-based electronic health records study. JAMA Psychiatry. 2016; 73: 630-637.
- 30Tondo L, Baldessarini RJ. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. Epidemiol Psichiatr Soc. 2009; 18: 179-183.
- 31Ougrin D, Tranah T, Stahl D, Moran P, Asarnow JR. Therapeutic interventions for suicide attempts and self-harm in adolescents: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2015; 54: 97-107.
- 32Hawton K, Witt KG, Taylor Salisbury TL, et al. Interventions for self-harm in children and adolescents. Cochrane Database Syst Rev. 2015; CD012013.
- 33Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry. 2007; 68: 380-383.
- 34Hawton K, Witt KG, Taylor Salisbury TL, et al. Pharmacological interventions for self-harm in adults. Cochrane Database Syst Rev. 2015; CD011777.
- 35Hawton K, Townsend E, Arensman E. Psychosocial and pharmacological treatments for deliberate self harm. Cochrane Database of Sys Rev. 1999.
- 36Oquendo MA, Galfalvy HC, Currier D, et al. Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry. 2011; 168: 1050-1056.
- 37Lauterbach E, Felber W, Müller-Oerlinghausen B, et al. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand. 2008; 118: 469-479.
- 38Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. Br Med J. 2011; 343: d5422.
- 39Khan A, Khan SR, Hobus J, et al. Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: role of lithium levels. J Psychiatr Res. 2011; 45: 1489-1496.
- 40Lewitzka U, Jabs B, Fülle M, et al. Does lithium reduce acute suicidal ideation and behavior? A protocol for a randomized, placebo-controlled multicenter trial of lithium plus Treatment As Usual (TAU) in patients with suicidal major depressive episode. BMC Psychiatry. 2015; 15: 117.
- 41Malhi GS. Lithium therapy in bipolar disorder: a balancing act? Lancet. 2015; 386: 415-416.
- 42Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002; 59: 530-537.
- 43Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003; 60: 261-269.
- 44Müller-Oerlinghausen B, Müser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord. 1992; 25: 261-269.
- 45Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry. 2001; 34: 132-136.
- 46Müller-Oerlinghausen B, Wolf T, Ahrens B, et al. Mortality during initial and during later lithium treatment. Acta Psychiatr Scand. 1994; 90: 295-297.
- 47Müller-Oerlinghausen B, Wolf T, Ahrens B, et al. Mortality of patients who dropped out from regular lithium prophylaxis: a collaborative study by the International Grow for the Study of Lithium-Treated Patients (IGSLI). Acta Psychiatr Scand. 1996; 94: 344-347.
- 48Coppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P, Hermon C. Long-term lithium and mortality. Lancet. 1990; 335: 1347.
- 49Wolf T, Müller-Oerlinghausen B, Ahrens B, et al. How to interpret findings on mortality of long-term lithium treated manic-depressive patients?! Critique of different methodological approaches. J Affect Disord. 1996; 39: 127-132.
- 50Rihmer Z, Gonda X. Pharmacological prevention of suicide in patients with major mood disorders. Neurosci Biobehav Rev. 2013; 37: 2398-2403.
- 51Tondo L, Baldessarini RJ, Hennen J, Floris G, Silvetti F, Tohen M. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry. 1998; 59: 405-414.
- 52Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry. 1998; 60: 77-84.
- 53Young AH. Lithium and suicide. Lancet Psychiatry. 2014; 1: 483-484.
- 54Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology. 2010; 62: 43-49.
- 55Kovacsics CE, Gottesman II, Gould TD. Lithium's antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol. 2009; 49: 175-198.
- 56Baldessarini RJ, Pompili M, Tondo L, et al. Antidepressants and suicidal behavior: are we hurting or helping. Clin Neuropsychiatry. 2005; 2: 75.
- 57Kalkman HO. Circumstantial evidence for a role of glutamine-synthetase in suicide. Med Hypotheses. 2011; 76: 905-907.
- 58Adida M, Jollant F, Clark L, et al. Lithium might be associated with better decision-making performance in euthymic bipolar patients. Eur Neuropsychopharmacol. 2015; 25: 788-797.
- 59Tondo L, Albert MJ, Baldessarini RJ. Suicide rates in relation to health care access in the United States: an ecological study. J Clin Psychiatry. 2006; 67: 517-523.
- 60Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry. 2003; 60: 82-91.
- 61Lee BH, Kim YK. Potential peripheral biological predictors of suicidal behavior in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35: 842-847.
- 62Mann JJ. A current perspective of suicide and attempted suicide. Ann Intern Med. 2002; 136: 302-311.
- 63Grof P, Müller-Oerlinghausen B. A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. Bipolar Disord. 2009; 11(s2): 10-19.
- 64Pfennig A, Bauer M. S3 guidelines on bipolar disorders are contemporary and important instruments for clinical practice. Nervenarzt. 2013; 84: 874-875.
- 65Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013; 14: 154-219.
- 66Kendall T, Morriss R, Mayo-Wilson E, Marcus E, Guideline Development Group of the National Institute for Health and Care Excellence. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ. 2014; 349: g5673.
- 67McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012; 379: 721-728.
- 68Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 2015; 386: 461-468.
- 69Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP. Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a population-based cohort study. PLoS Med. 2016; 13: e1002058.
- 70Smith EG, Austin KL, Kim HM, et al. Mortality associated with lithium and valproate treatment of US Veterans Health Administration patients with mental disorders. Br J Psychiatry. 2015; 207: 55-63.
- 71Hansen HE, Amdisen A. Lithium intoxication. (Report of 23 cases and review of 100 cases from the literature). Q J Med. 1978; 47: 123-144.
- 72Vestergaard P, Aagaard J. Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord. 1991; 21: 33-38.
- 73Waddington D, McKenzie IP. Overdose rates in lithium-treated versus antidepressant-treated outpatients. Acta Psychiatr Scand. 1994; 90: 50-52.
- 74Watson WA, Litovitz TL, Klein-Schwartz W, et al. 2003 Annual report of the American association of poison control centers Toxic Exposure Surveillance System (TESS). Am J Emerg Med. 2004; 22: 386-392.
- 75Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013; 381: 1672-1682.
- 76Malhi GS, Geddes JR. Carving bipolarity using a lithium sword. Br J Psychiatry. 2014; 205: 337-339.
- 77Saunders KE, Cipriani A, Rendell J, et al. Oxford Lithium Trial (OxLith) of the early affective, cognitive, neural and biochemical effects of lithium carbonate in bipolar disorder: study protocol for a randomised controlled trial. Trials. 2016; 17: 116.
- 78Bonsall MB, Wallace-Hadrill SM, Geddes JR, Goodwin GM, Holmes EA. Nonlinear time-series approaches in characterizing mood stability and mood instability in bipolar disorder. Proc Biol Sci. 2012; 279: 916-924.
- 79Bopp JM, Miklowitz DJ, Goodwin GM, Stevens W, Rendell JM, Geddes JR. The longitudinal course of bipolar disorder as revealed through weekly text messaging: a feasibility study. Bipolar Disord. 2010; 12: 327-334.
- 80Benazzi F. Characteristics of bipolar II patients with interpersonal rejection sensitivity. Psychiatry Clin Neurosci. 2000; 54: 499-501.
- 81Baldessarini RJ, Tondo L, Hennen J. Treating the suicidal patient with bi-polar disorder: reducing suicide risk with lithium. Ann N Y Acad Sci. 2001; 932: 24-43.
- 82Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand. 2001; 104: 163-172.
- 83Tondo L, Pompili M, Forte A, Baldessarini RJ. Suicide attempts in bipolar disorders: comprehensive review of 101 reports. Acta Psychiatr Scand. 2016; 133: 174-186.
- 84Burgess S, Geddes J, Hawton K et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev. 2001; CD003013.
- 85Cipriani A, Smith K, Burgess S, Carney S, Goodwin G, Geddes J. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev. 2006; CD003492.
- 86Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6: e1000097.
- 87Malhi GS, Gershon S, Outhred T. Lithiumeter: version 2.0. Bipolar Disord. 2016; 18: 631-641.
- 88Malhi GS, McAulay C, Gershon S, et al. The lithium battery: assessing the neurocognitive profile of lithium in bipolar disorder. Bipolar Disord. 2016; 18: 102-115.
- 89Yerevanian BI, Choi YM. Impact of psychotropic drugs on suicide and suicidal behaviors. Bipolar Disord. 2013; 15: 594-621.
- 90Zalsman G, Hawton K, Wasserman D, et al. Suicide prevention strategies revisited: 10-year systematic review. The Lancet Psychiatry. 2016; 3: 646-659.
- 91Baldessarini RJ, Tondo L. Suicidal risks during treatment of bipolar disorder patients with lithium versus anticonvulsants. Pharmacopsychiatry. 2009; 42: 72-75.
- 92Rosenthal R. Writing meta-analytic reviews. Psychol Bull. 1995; 118: 183-192.
- 93Riblet NB, Shiner B, Young-Xu Y, Watts BV. Strategies to prevent death by suicide: meta-analysis of randomised controlled trials. Br J Psychiatry. 2017; 210: 396-402.
- 94Girlanda F, Cipriani A, Agrimi E, et al. Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: results and lessons of an underpowered randomised clinical trial. BMC Res Notes. 2014; 7: 731.
